-
H.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics
Tuesday, June 28, 2016 - 10:11am | 361Read More...H.C. Wainwright’s Swayampakula Ramakanth believes if the VTS gene therapy platform is successfully developed by Vascular Biogenics Ltd (NASDAQ: VBLT), it could revolutionize the multi-billion dollar angiogenesis inhibitor market. Ramakanth initiated coverage of the company with a Buy rating...
